{"contentid": 488467, "importid": NaN, "name": "Daiichi Sankyo links with Esperion to market bempedoic acid in new region", "introduction": "Japan\u00e2\u0080\u0099s Daiichi Sankyo has entered into an exclusive licensing agreement with Esperion Therapeutics to market bempedoic acid (trade-named Nilemdo in some markets), its proprietary oral once-daily drug for the treatment of hypercholesterolemia, in South Korea, Brazil, Taiwan, Hong Kong, Macao, Thailand, Vietnam, Myanmar and Cambodia (the Region).", "content": "<p>Japan&rsquo;s Daiichi Sankyo (TYO: 4568) has entered into an exclusive licensing agreement with Esperion Therapeutics (Nasdaq: ESPR) to market bempedoic acid (trade-named Nilemdo in some markets), its proprietary oral once-daily drug for the treatment of hypercholesterolemia, in South Korea, Brazil, Taiwan, Hong Kong, Macao, Thailand, Vietnam, Myanmar and Cambodia (the Region).</p>\n<p>Under the accord, Daiichi Sankyo will be responsible for the commercialization of bempedoic acid and the bempedoic acid/ezetimibe combination, while Esperion will be responsible for their manufacture.</p>\n<p>In terms of the development operations required for regional applications, Esperion will undertake operations in South Korea and Taiwan, and Daiichi Sankyo will undertake operations in the other territories.</p>\n<h2><strong>Upfront $30 million for Esperion</strong></h2>\n<p>Also, Daiichi Sankyo will make an upfront payment of $30 million to Esperion in addition to future, undisclosed milestone payments and sales royalties.</p>\n<p>With a novel mechanism of action, bempedoic acid is a drug that inhibits cholesterol and fatty acid biosynthesis by acting on ATP Citrate Lyase, an enzyme that cleaves citrate in the liver. Bempedoic acid was approved in February 2020 in the USA and in April of the same year in Europe Union, and its commercialization has been managed by Esperion in the USA and by Daiichi Sankyo Europe GmbH, a subsidiary of Daiichi Sankyo, in Europe.</p>\n<p>The commercialization of bempedoic acid in the Region can take advantage of Daiichi Sankyo&rsquo;s marketing prowess in the cardiovascular field which was established with the anticoagulant Lixiana (edoxaban) and other CV products, thus boosting Daiichi Sankyo&rsquo;s regional value.</p>", "date": "2021-04-27 12:35:00", "meta_title": "Daiichi Sankyo links with Esperion to market bempedoic acid in new reg", "meta_keywords": "Daiichi Sankyo, Esperion Therapeutics, License, Agreement, Bempedoic acid, Nilemdo, Hypercholesterolemia, Marketing", "meta_description": "Daiichi Sankyo links with Esperion to market bempedoic acid in new region", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-27 12:34:52", "updated": "2021-04-27 12:44:53", "access": NaN, "url": "https://www.thepharmaletter.com/article/daiichi-sankyo-links-with-esperion-to-market-bempedoic-acid-in-new-region", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "daiichi-hq.jpg", "image2id": "daiichi-hq-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Cardio-vascular", "topic_tag": "Asia Pacific, Deals, Focus On, Licensing", "geography_tag": "Asia-Pacific, Brazil, Japan, USA", "company_tag": "Daiichi Sankyo, Esperion Therapeutics", "drug_tag": "bempedoic acid, Nilemdo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-27 12:35:00"}